Literature DB >> 8841711

Delayed facial palsy after acoustic neuroma resection: the role of viral reactivation.

G J Gianoli1, J M Kartush.   

Abstract

Delayed facial palsy after acoustic neuroma resection may occur in up to 15% of cases. Prognosis is generally good if the palsy does not progress to total paralysis. However, a delayed palsy with subsequent total paralysis has a more variable final outcome, which ranges from normal function to permanent total paralysis. This delayed paralysis has been attributed to edema from surgical manipulation of the facial nerve. Steroids and intraoperative decompression of the meatal foramen have been used with some success, but some cases remain refractory to these measures. Herpes simplex virus and varicella-zoster virus are ubiquitous in the population and remain in a latent state in neural ganglia. These viruses are reactivated during times of stress. Trigeminal nerve surgery (partial sensory rhizotomy and microvascular decompression) stimulates reactivation of herpes simplex with manifestations in the sensory distribution of the trigeminal nerve in 38-94% of procedures. Prevention of this reactivation has been demonstrated in placebo-controlled trials by using prophylactic acyclovir. We present a patient who underwent translabyrinthine resection of an intracanalicular acoustic neuroma and in whom developed otalgia, vesicles on the ear canal and the ipsilateral buccal mucosa, and progressive facial palsy the week after surgery. Serologic evaluation confirmed the diagnosis of herpes zoster oticus. Reactivation of latent virus apparently occurred as a result of surgical manipulation of the facial nerve. This parallels viral reactivation seen in trigeminal nerve surgery. We propose a new theory for an additional cause of delayed facial palsy after acoustic neuroma resection-reactivation of latent herpesvirus resulting from surgical trauma. Acyclovir should be evaluated in clinical trials for a prophylactic role in patients undergoing acoustic neuroma resection or a therapeutic role in patients in whom a delayed postoperative facial palsy develops.

Entities:  

Mesh:

Year:  1996        PMID: 8841711

Source DB:  PubMed          Journal:  Am J Otol        ISSN: 0192-9763


  7 in total

1.  Nerve crush but not displacement-induced stretch of the intra-arachnoidal facial nerve promotes facial palsy after cerebellopontine angle surgery.

Authors:  Habib Bendella; Derald E Brackmann; Roland Goldbrunner; Doychin N Angelov
Journal:  Exp Brain Res       Date:  2016-06-08       Impact factor: 1.972

2.  Postoperative hematoma can be a risk factor in delayed facial palsy after vestibular schwannoma resection via a retrosigmoid approach: a retrospective single-center cohort study.

Authors:  Kohei Kanaya; Tetsuyoshi Horiuchi
Journal:  Acta Neurol Belg       Date:  2022-06-08       Impact factor: 2.396

3.  Pre- and intra-operative prognostic factors of facial nerve function in cerebellopontine angle surgery.

Authors:  Francesco Gazia; Àngela Callejo; Marta Pérez-Grau; Susana Lareo; José Prades; Francesc Roca-Ribas; Emilio Amilibia
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-07-30       Impact factor: 3.236

4.  The effects of dexamethasone and acyclovir on a cell culture model of delayed facial palsy.

Authors:  Meghan T Turner; Shruti Nayak; Maggie Kuhn; Pamela Carol Roehm
Journal:  Otol Neurotol       Date:  2014-04       Impact factor: 2.311

5.  Delayed Facial Paralysis following Uneventful KTP Laser Stapedotomy: Two Case Reports and a Review of the Literature.

Authors:  P Révész; Z Piski; A Burián; K Harmat; I Gerlinger
Journal:  Case Rep Med       Date:  2014-11-11

6.  Delayed Facial Palsy after Microvascular Decompression: Report of Two Cases.

Authors:  G Lakshmi Prasad; Vinod Kumar; Girish Menon
Journal:  J Neurosci Rural Pract       Date:  2017 Jul-Sep

Review 7.  A Review of Delayed Facial Nerve Paresis as Complication Following Total Endoscopic Ear Surgery.

Authors:  Tengku Mohamed Izam Tengku Kamalden; Asfa Najmi Mohamad Yusof; Khairunnisak Misron
Journal:  J Int Adv Otol       Date:  2021-11       Impact factor: 1.017

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.